Yibin Wang

Title: Yibin Wang: Innovator in Cardiac Gene Therapy

Introduction

Yibin Wang is a prominent inventor based in Brookville, MD (US). He has made significant contributions to the field of gene therapy, particularly in cardiac applications. His innovative work has led to the development of a unique recombinant adenovirus vector aimed at enhancing tissue-specific expression in the heart.

Latest Patents

Wang holds a patent for a recombinant adenovirus designed for cardiac restricted transcription. This invention utilizes the cardiomyocyte-restricted cardiac ankyrin repeat protein (CARP) promoter, along with inverted terminal repeat sequences from human adeno-associated virus (AAV). The recombinant adenovirus vector, known as Ad/CG/ITR, has been shown to effectively direct transgene expression to myocardial tissue in both in vivo and in vitro mouse models, using green fluorescent protein (GFP) as a marker gene. He has 1 patent to his name.

Career Highlights

Yibin Wang is affiliated with the University of California, where he continues to advance research in cardiac gene therapy. His work is characterized by a commitment to improving therapeutic strategies for heart diseases through innovative genetic approaches.

Collaborations

Wang has collaborated with notable colleagues in his field, including Sylvia Evans and Kenneth R. Chien. These partnerships have further enriched his research and contributed to the advancement of cardiac therapies.

Conclusion

Yibin Wang's contributions to cardiac gene therapy through his innovative patent demonstrate his dedication to improving health outcomes in heart disease. His work continues to inspire advancements in the field of medical research.